Shehnaaz Suliman, ReCode Therapeutics CEO (Photo by Jennifer Leahy)

Pfiz­er, Sanofi-backed LNP out­fit goes back to the well and draws $120M for its trek to the clin­ic

A pre­clin­i­cal biotech tout­ing a five-lipid drug de­liv­ery plat­form is look­ing to break out of its pre­clin­i­cal mold, and it just se­cured a siz­able raise to do just that.

Re­Code Ther­a­peu­tics re­port­ed Wednes­day morn­ing that Leaps by Bay­er and Ma­trix Cap­i­tal Man­age­ment af­fil­i­ate Ayur­Maya co-led a Se­ries B ex­ten­sion round, adding $120 mil­lion to the biotech’s pre­vi­ous Se­ries B haul of $80 mil­lion. The biotech has been backed by sev­er­al play­ers in Big Phar­ma, no­tably Pfiz­er and Sanofi from its orig­i­nal Se­ries B close last fall. And in this ex­ten­sion — fea­tur­ing all new in­vestors, CEO Shehnaaz Suli­man tells End­points News — Am­gen’s VC arm jumped on board.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.